<DOC>
	<DOCNO>NCT00829829</DOCNO>
	<brief_summary>The purpose clinical research study determine safety effectiveness experimental drug call rilonacept subject gout begin allopurinol treatment gout . Subjects participate study approximately 22 week . Rilonacept study use prevent allopurinol-induced gout flare .</brief_summary>
	<brief_title>PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Male female 18 80 year age Previously meet preliminary criterion ARA classification acute arthritis primary gout At least 2 gout flare year prior Screening Visit Serum uric acid great equal 7.5 mg/dL Screening Visit Acute gout flare within 2 week Screening Visit Screening Persistent chronic active infection History allergic reaction allopurinol History presence cancer within 5 year Screening Visit Previous exposure rilonacept Use allopurinol , benzbromarone , febuxostat , probenecid sulfinpyrazone within 3 month prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Metabolism , Inborn Errors</keyword>
	<keyword>Allopurinol</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Rheumatic Diseases</keyword>
	<keyword>Metabolic disorder</keyword>
	<keyword>Purine-Pyrimidine Metabolism , Inborn Errors</keyword>
	<keyword>Gout</keyword>
</DOC>